Literature DB >> 8959316

Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women.

M J Reeves1, P A Newcomb, A Trentham-Dietz, B E Storer, P L Remington.   

Abstract

Several epidemiological studies have identified an association between nonsteroidal anti-inflammatory drug (NSAID) use and colorectal cancer risk in women. We examined this association in a population-based case-control study in Wisconsin women. Between 1991 and 1992, 184 women ages 40-74 years with colorectal cancer were identified through the statewide cancer registry and 293 population-based control women were randomly selected via telephone. Regular NSAID use was defined as at least twice weekly for 12 months or longer. After adjusting the data for age, controls were more likely than cases to report regular NSAID use (38 versus 27%). Following adjustment for age, prior sigmoidoscopy use, family history of large bowel cancer, and body mass index, women who regularly used NSAIDs were approximately one-third less likely to be diagnosed with colorectal cancer compared to women who did not use NSAIDs [odds ratio (OR), 0.65; 95% confidence interval (CI), 0.40-1.03]. A statistically significant effect of duration of use was identified, although the ORs did not show a consistent trend. No significant effect of frequency of NSAID use was observed. When the type of NSAID used was examined (aspirin or nonaspirin), subjects who used nonaspirin compounds had a statistically significantly lower risk of colorectal cancer (OR, 0.43; 95% CI, 0.20-0.89), compared to nonusers, whereas aspirin users had only a small, nonsignificant reduction in cancer risk (OR, 0.79; 95% CI, 0.46-1.36). These data add support to the hypothesis that regular NSAID use is associated with lower colorectal cancer risk in women and suggest that the type of NSAID used may be important.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8959316

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  19 in total

1.  Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer.

Authors:  Andrew T Chan; Edward L Giovannucci; Jeffrey A Meyerhardt; Eva S Schernhammer; Gary C Curhan; Charles S Fuchs
Journal:  JAMA       Date:  2005-08-24       Impact factor: 56.272

Review 2.  Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.

Authors:  Jocelyn Reader; Dawn Holt; Amy Fulton
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 3.  Do older adults using NSAIDs have a reduced risk of colorectal cancer?

Authors:  Michael Hoffmeister; Jenny Chang-Claude; Hermann Brenner
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 4.  Chemoprevention of Colorectal Cancer.

Authors:  Bryson W Katona; Jennifer M Weiss
Journal:  Gastroenterology       Date:  2019-09-26       Impact factor: 22.682

5.  Correlation between expression of cyclooxygenase-2 and angiogenesis in human gastric adenocarcinoma.

Authors:  Hong-Xia Li; Xin-Ming Chang; Zheng-Jun Song; Shui-Xiang He
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

6.  Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome.

Authors:  Driss Ait Ouakrim; Seyedeh Ghazaleh Dashti; Rowena Chau; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Ingrid M Winship; Joanne P Young; Graham G Giles; Barbara Leggett; Finlay A Macrae; Dennis J Ahnen; Graham Casey; Steven Gallinger; Robert W Haile; Loïc Le Marchand; Stephen N Thibodeau; Noralane M Lindor; Polly A Newcomb; John D Potter; John A Baron; John L Hopper; Mark A Jenkins; Aung Ko Win
Journal:  J Natl Cancer Inst       Date:  2015-06-24       Impact factor: 13.506

Review 7.  Primary prevention of colorectal cancer.

Authors:  Andrew T Chan; Edward L Giovannucci
Journal:  Gastroenterology       Date:  2010-06       Impact factor: 22.682

Review 8.  [Epidemiological studies for evaluating the role of cyclooxygenase in chemoprevention of malignant tumors].

Authors:  Eva S Schernhammer; Christian Dittrich
Journal:  Wien Med Wochenschr       Date:  2003

9.  Aspirin dose and duration of use and risk of colorectal cancer in men.

Authors:  Andrew T Chan; Edward L Giovannucci; Jeffrey A Meyerhardt; Eva S Schernhammer; Kana Wu; Charles S Fuchs
Journal:  Gastroenterology       Date:  2007-09-26       Impact factor: 22.682

10.  Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells.

Authors:  Satya Prakash; Aleksandra Malgorzata Urbanska
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.